Clinical applications of microRNAs [v2; ref status: indexed, http://f1000r.es/1o3]

MicroRNAs represent a class of small RNAs derived from polymerase II controlled transcriptional regions. The primary transcript forms one or several bulging double stranded hairpins which are processed by Drosha and Dicer into hetero-duplexes. The targeting microRNA strand of the duplex is incorpora...

Full description

Bibliographic Details
Main Authors: Per Hydbring, Gayane Badalian-Very
Format: Article
Language:English
Published: F1000 Research Ltd 2013-08-01
Series:F1000Research
Subjects:
Online Access:http://f1000research.com/articles/2-136/v2
id doaj-20cfbdf44e594b2e82342cac93c3ff5b
record_format Article
spelling doaj-20cfbdf44e594b2e82342cac93c3ff5b2020-11-25T03:12:08ZengF1000 Research LtdF1000Research2046-14022013-08-01210.12688/f1000research.2-136.v22163Clinical applications of microRNAs [v2; ref status: indexed, http://f1000r.es/1o3]Per Hydbring0Gayane Badalian-Very1Department of Genetics and Medicine, Harvard Medical School, Boston MA, 02115, USADepartment of Medicine, Brigham and Women's Hospital, Boston MA, 02115, USAMicroRNAs represent a class of small RNAs derived from polymerase II controlled transcriptional regions. The primary transcript forms one or several bulging double stranded hairpins which are processed by Drosha and Dicer into hetero-duplexes. The targeting microRNA strand of the duplex is incorporated into the RNA Induced Silencing Complex from where it silences up to hundreds of mRNA transcript by inducing mRNA degradation or blocking protein translation. Apart from involvement in a variety of biological processes, microRNAs were early recognized for their potential in disease diagnostics and therapeutics. Due to their stability, microRNAs could be used as biomarkers. Currently, there are microRNA panels helping physicians determining the origins of cancer in disseminated tumors. The development of microRNA therapeutics has proved more challenging mainly due to delivery issues. However, one drug is already in clinical trials and several more await entering clinical phases. This review summarizes what has been recognized pre-clinically and clinically on diagnostic microRNAs. In addition, it highlights individual microRNA drugs in running platforms driven by four leading microRNA-therapeutic companies.http://f1000research.com/articles/2-136/v2Cancer TherapeuticsMedical Genetics
collection DOAJ
language English
format Article
sources DOAJ
author Per Hydbring
Gayane Badalian-Very
spellingShingle Per Hydbring
Gayane Badalian-Very
Clinical applications of microRNAs [v2; ref status: indexed, http://f1000r.es/1o3]
F1000Research
Cancer Therapeutics
Medical Genetics
author_facet Per Hydbring
Gayane Badalian-Very
author_sort Per Hydbring
title Clinical applications of microRNAs [v2; ref status: indexed, http://f1000r.es/1o3]
title_short Clinical applications of microRNAs [v2; ref status: indexed, http://f1000r.es/1o3]
title_full Clinical applications of microRNAs [v2; ref status: indexed, http://f1000r.es/1o3]
title_fullStr Clinical applications of microRNAs [v2; ref status: indexed, http://f1000r.es/1o3]
title_full_unstemmed Clinical applications of microRNAs [v2; ref status: indexed, http://f1000r.es/1o3]
title_sort clinical applications of micrornas [v2; ref status: indexed, http://f1000r.es/1o3]
publisher F1000 Research Ltd
series F1000Research
issn 2046-1402
publishDate 2013-08-01
description MicroRNAs represent a class of small RNAs derived from polymerase II controlled transcriptional regions. The primary transcript forms one or several bulging double stranded hairpins which are processed by Drosha and Dicer into hetero-duplexes. The targeting microRNA strand of the duplex is incorporated into the RNA Induced Silencing Complex from where it silences up to hundreds of mRNA transcript by inducing mRNA degradation or blocking protein translation. Apart from involvement in a variety of biological processes, microRNAs were early recognized for their potential in disease diagnostics and therapeutics. Due to their stability, microRNAs could be used as biomarkers. Currently, there are microRNA panels helping physicians determining the origins of cancer in disseminated tumors. The development of microRNA therapeutics has proved more challenging mainly due to delivery issues. However, one drug is already in clinical trials and several more await entering clinical phases. This review summarizes what has been recognized pre-clinically and clinically on diagnostic microRNAs. In addition, it highlights individual microRNA drugs in running platforms driven by four leading microRNA-therapeutic companies.
topic Cancer Therapeutics
Medical Genetics
url http://f1000research.com/articles/2-136/v2
work_keys_str_mv AT perhydbring clinicalapplicationsofmicrornasv2refstatusindexedhttpf1000res1o3
AT gayanebadalianvery clinicalapplicationsofmicrornasv2refstatusindexedhttpf1000res1o3
_version_ 1724651317622734848